Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Biologists Reprogram Skin Cells to Mimic Rare Disease - 08/21/2014
Biologists Reprogram Skin Cells to Mimic Rare Disease
Additional tool accelerates personalized medicine research
Release Date: August 21, 2014
Neural crest cells were made from reprogrammed adult skin cells. A single neural crest cell divided many times and these cells (green) were coaxed to become four different types of adult cells, as shown by the presence of cell-specific proteins (red). Clockwise from upper left corner: nerve cells, smooth muscle cells, pigment-producing skin cells and cells that protect and support nerve cells.
courtesy Cell Press
- Neural crest cells give rise to most of the nerves outside of the brain and spinal cord, pigment-producing skin cells, and skull bones.
- Scientists reprogrammed skin cells from patients with a rare genetic disease to create neural crest cells that mirror many aspects of the cells that cause the disease.
- Cells will help researchers better study the disease and develop potential treatments.
Johns Hopkins stem cell biologists have found a way to reprogram a patient’s skin cells into cells that mimic and display many biological features of a rare genetic disorder called familial dysautonomia. The process requires growing the skin cells in a bath of proteins and chemical additives while turning on a gene to produce neural crest cells, which give rise to several adult cell types. The researchers say their work substantially expedites the creation of neural crest cells from any patient with a neural crest-related disorder, a tool that lets physicians and scientists study each patient’s disorder at the cellular level.
Previously, the same research team produced customized neural crest cells by first reprogramming patient skin cells into induced pluripotent stem (iPS) cells, which are similar to embryonic stem cells in their ability to become any of a broad array of cell types.
“Now we can circumvent the iPS cells step, saving seven to nine months of time and labor and producing neural crest cells that are more similar to the familial dysautonomia patients’ cells,” says Gabsang Lee, Ph.D., an assistant professor of neurology at the Institute for Cell Engineering and the study’s senior author. A summary of the study was published online in the journal Cell Stem Cell on Aug. 21.
Neural crest cells appear early in human and other animal prenatal development, and they give rise to many important structures, including most of the nervous system (apart from the brain and spinal cord), the bones of the skull and jaws, and pigment-producing skin cells. Dysfunctional neural crest cells cause familial dysautonomia, which is incurable and can affect nerves’ ability to regulate emotions, blood pressure and bowel movements. Less than 500 patients worldwide suffer from familial dysautonomia, but dysfunctional neural crest cells can cause other disorders, such as facial malformations and an inability to feel pain.
The challenge for scientists has been the fact that by the time a person is born, very few neural crest cells remain, making it hard to study how they cause the various disorders.
To make patient-specific neural crest cells, the team began with laboratory-grown skin cells that had been genetically modified to respond to the presence of the chemical doxycycline by glowing green and turning on the gene Sox10, which guides cells toward maturation as a neural crest cell.
Testing various combinations of molecular signals and watching for telltale green cells, the team found a regimen that turned 2 percent of the cells green. That combination involved turning on Sox10 while growing the cells on a layer of two different proteins and giving them three chemical additives to “rewind” their genetic memory and stimulate a protein network important for development.
Analyzing the green cells at the single cell level, the researchers found that they showed gene activity similar to that of other neural crest cells. Moreover, they discovered that 40 percent were “quad-potent,” or able to become the four cell types typically derived from neural crest cells, while 35 percent were “tri-potent” and could become three of the four. The cells also migrated to the appropriate locations in chick embryos when implanted early in development.
The team then applied a modified version of the technique to skin cells from healthy adults and found that the skin cells became neural crests at a rate similar to the team’s previous experiments.
Finally, the investigators used their regimen on skin cells from patients with familial dysautonomia, then compared these familial dysautonomia-neural crest cells to the control neural crest cells made from healthy adults. They identified 412 genes with lower activity levels in the familial dysautonomia-neural crest cells, of which 98 are involved in processing RNA products made from active genes.
According to the authors, this new observation offers insight into what goes wrong in familial dysautonomia.
“It seems as though the neural crest cells created directly from patient skin cells show more of the characteristics of familial dysautonomia than the neural crest cells we created previously from induced pluripotent stem cells,” says Lee. “That means they should be better predictors of what happens in a particular familial dysautonomia patient, and whether or not a potential treatment will work for any given individual.”
The method they devised should also be applicable to skin cells taken from people with any of the other diseases that result from dysfunctional neural crest cells, such as congenital pain disorders and Charcot-Marie-Tooth diseases, Lee says.
Other authors of the report include Yong Jun Kim, HoTae Lim, Zhe Li, Yohan Oh, Irina Kovlyagina, InYoung Choi and Xinzhong Dong of the Johns Hopkins University School of Medicine.
This work was supported by grants from the New York Stem Cell Foundation (Robertson Investigator Award) and the Maryland Stem Cell Research Fund (TEDCO).
On the Web:
For the Media
Photo to accompany this story is available for download.
We are providing this photo with the understanding that it will be used only to help illustrate the story in the corresponding news release. Please use the credit information given. If there is anything else you need, please email us at JHMedia@jhmi.edu. Thank you.